“Hemophilia”

7 result(s)
Drug Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing
Drug Pipeline
The gene therapy pipeline report highlights what payors can expect for a variety of conditions. More
Briefing
Near-Term Outlook for Projected Gene Therapies and Their Approval Timelines | Payor Solutions
Drug Pipeline
Projected Approvals of Pipeline Gene Therapies Expected to Treat Conditions with Few Options More
Briefing
Pipeline Therapies Could Expand Choices for Conditions with Limited Options | Payor Solutions | CVS Health
Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Cost Management
CVS Health offers payors a new stop-loss program and installment payment plan to help mitigate the large one-time impact of costly gene therapies. These approaches are part of... More
Briefing
View article
Drug Pipeline
Updates on the robust gene therapy pipeline from CVS Health pipeline team to help payors stay abreast of this very important emerging category. More
Briefing